Proteolytic Enzyme Combination Reduces Inflammation and Oxidative Stress and Improves Insulin Sensitivity in a Model of Metabolic Syndrome


Chronic, low-level inflammation may be an independent marker of Metabolic Syndrome (MetS). Systemic Enzyme Therapy (SET), the oral administration of proteolytic enzymes, is safe and effective in the management of inflammation. Therefore, the effects of SET, as Wobenzym®, on the prevention and treatment of inflammation and other metabolic risk factors were assessed in a rabbit model of diet-induced MetS. Animals were fed a lipid-enriched diet for 8 weeks during which they were administered a vehicle control (control group) or Wobenzym either throughout the study period (prevention group) or beginning at the 5th week, after the development of biomarkers of MetS (treatment group). At the 8th week, both prevention and treatment groups demonstrated improved insulin sensitivity relative to the control group and reduced serum C-reactive protein (CRP) and glycosylated hemoglobin (HbA1c, P < 0.001). At 8 weeks, the prevention group, but not the treatment group, exhibited reduced total cholesterol and oxidative stress, measured as serum malondialdehyde (P < 0.001). Triglycerides and free fatty acids were reduced in both the treatment (P < 0.01) and prevention groups (P < 0.001) relative to the control group at the 8th week. Body weight and blood glucose were not affected. Enzyme therapy may have a positive effect on inflammation, insulin sensitivity, and other metabolic risk factors of MetS.

Share and Cite:

Talaieva, T. and Bratus, V. (2015) Proteolytic Enzyme Combination Reduces Inflammation and Oxidative Stress and Improves Insulin Sensitivity in a Model of Metabolic Syndrome. Advances in Enzyme Research, 3, 1-8. doi: 10.4236/aer.2015.31001.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Alberti, K.G., Zimmet, P. and Shaw, J. (2005) The Metabolic Syndrome—A New Worldwide Definition. The Lancet, 366, 1059-1062.
[2] Goldstein, L.B., Bushnell, C.D., Adams, R.J., Appel, L.J., Braun, L.T., Chaturvedi, S., Creager, M.A., Culebras, A., Eckel, R.H., Hart, R.G., Hinchey, J.A., Howard, V.J., Jauch, E.C., Levine, S.R., Meschia, J.F., Moore, W.S., Nixon, J.V., Pearson, T.A., American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Epidemiology and Prevention, Council for High Blood Pressure Research, Council on Peripheral Vascular Disease, and Interdisciplinary Council on Quality of Care and Outcomes Research (2011) Guidelines for the Primary Prevention of Stroke: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke, 42, 517-584.
[3] Finkelstein, E.A., Trogdon, J.G., Cohen, J.W. and Dietz, W. (2009) Annual Medical Spending Attributable to Obesity: Payer- and Service-Specific Estimates. Health Affairs (Millwood), 28, W822-W831.
[4] Center for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion. (2011) National Diabetes Fact Sheet.
[5] Holvoet, P., Lee, D.-H., Steffes, M., Gross, M. and Jacobs, D.R. (2008) Association between Circulating Oxidized Low-Density Lipoprotein and Incidence of the Metabolic Syndrome. The Journal of the American Medical Association, 299, 2287-2293.
[6] Sun, S.Y., Ji, Y.W., Kersten, S. and Ling, Q. (2012) Mechanisms of Inflammatory Responses in Obese Adipose Tissue. Annual Review of Nutrition, 32, 261-286.
[7] Deveraj, S., Siegel, D. and Jialal, I. (2011) Statin Therapyin Metabolic Syndrome and Hypertension Post-JUPITER: What Is the Value of CRP? Current Atherosclerosis Reports, 13, 31-42.
[8] Den Englensen, C., Koekkoek, P.S., Gorter, P.J., van den Donk, M., Salomé, P.L. and Rutten, G.E. (2012) High-Sensitivity C-Reactive Protein to Detect Metabolic Syndrome in a Centrally Obese Population: A Cross-Sectional Analysis. Cardiovascular Diabetology, 11, 25.
[9] Kones, R. (2010) Rosuvastatin, Inflammation, C-Reactive Protein, JUPITER, and Primary Prevention of Cardiovascular Disease—A Perspective. Drug Design, Development and Therapy, 4, 383-413.
[10] Ridker, P.M. (2004) High-Sensitivity C-Reactive Protein, Inflammation, and Cardiovascular Risk: From Concept to Clinical Practice to Clinical Benefit. American Heart Journal, 148, S19-S26.
[11] Panchal, S.K., Poudyal, H., Arumugam, T.V. and Brown, L. (2011) Rutin Attenuates Metabolic Changes, Nonalcoholic Steatohepatitis, and Cardiovascular Remodeling in High-Carbohydrate, High-Fat Diet-Fed Rats. Journal of Nutrition, 141, 1062-1069.
[12] Lorkowski, G. (2012) Gastrointestinal Absorption and Biological Activities of Serine and Cysteine Proteases of Animaland Plant Origin: Review on Absorption of Serine and Cysteine Proteases. International Journal of Physiology and Pathophysiology, 4, 10-27.
[13] Rovenská, E., Svík, K., Stancíková, M. and Rovensky, J. (1999) Enzyme and Combination Therapy with Cyclosporin A in the Rat Developing Adjuvant Arthritis. International Journal of Tissue Reactions, 21, 105-111.
[14] Rovenská, E., Svík, K., Stancíková, M., and Rovensky, J. (2001) Inhibitory Effect of Enzyme Therapy and Combination Therapy with Cyclosporin A on Collagen-Induced Arthritis. Clinical and Experimental Rheumatology, 19, 303- 309.
[15] Singer, F. and Oberleitner, H. (1996) Ein Beitrag zur medikamentösen Therapie der aktivierten Arthrose. Zur Effektivität eines Enzymgemisches versus Diclofenac. Wiener Meidizinische Wochenschrift, 3, 55-58.
[16] Skutelis, A., Pule, E., Purvins, I., Baltkajs, J., Skromanis, M., Zeibarts, M., Desser. L., Osterreicher, J. and Ansberg, J. (2001) Phlogenzym May Prevent Metabolic Injuries to Myocardium Results of a Laboratory Experiment with Rats. International Journal of Immunotherapy, 17, 59-64.
[17] Duskova, M. and Wald, M. (1999) Orally Administered Proteases in Aesthetic Surgery. Aesthetic Plastic Surgery, 23, 41-44.
[18] Klein, G., Kullich, W. and Schwann, H. (1995) Double-Blind Trial of an Enzyme Therapy versus Oral Gold in Rheumatoid Arthritis. Clinicum, 3, 2-8.
[19] Kleine, M.W. (1990) Systemische enzymtherapie in der sportmedizin-grundlagen, wirkmechanismen, indikationen. Deutsche Zeitschriftfür Sportmedizin, 41, 126-134.
[20] Vinzenz, K. (1991) Ödembehandlung bei zahnchirurgischen eingriffen mit hydrolytischen enzymen. Chirurgische Zahnheilkunde, 7, 1053-1064.
[21] Kasseroller, R. and Wenning, H.G. (2003) Efficacy and Tolerability of Proteolytic Enzymes as an Anti-Inflammatory Agent in Lymphoedema after Axillary Dissection due to Mammary Cancer. The European Journal of Lymphology, 37-38, 18-26.
[22] Diehl, K.-H., Hull, R., Morton, D., Pfister, R., Rabemampianina, Y., Smith, D., Vidal, J.-M. and van de Vorstenbosch, C. (2001) A Good Practice Guide to the Administration of Substances and Removal of Blood, Including Routes and Volumes. Journal of Applied Toxicology, 21, 15-23.
[23] Arakawa, Y., Kurokawa, N., Maeda, Y. and Yanaihara, C. (1989) Change in Solubility of Insulin in Therapeutic Mixtures of Insulin Preparations: HPLC Analysis. Diabetes Research and Clinical Practice, 7, 93-100.
[24] Kainuma, M., Fujimoto, M., Sekiya, N., Tsuneyama, K., Cheng, C., Takano, Y., Terasawa, K. and Shimada, Y. (2006) Cholesterol-Fed Rabbit as a Unique Model of Nonalcoholic, Nonobese, Non-Insulin-Resistant Fatty Liver Disease with Characteristic Fibrosis. Journal of Gastroenterology, 41, 971-980.
[25] Zhao, S., Chu, Y., Zhang, C., Lin, Y., Xu, K., Yang, P., Fan, J. and Liu, E. (2008) Diet-Induced Central Obesity and Insulin Resistance in Rabbits. Journal of Animal Physiology and Animal Nutrition, 92, 105-111.
[26] Li, H., Dai, M., and Jia, W. (2009) Paeonol Attenuates High-Fat-Diet-Induced Atherosclerosis in Rabbits by Anti-Inflammatory Activity. Planta Medica, 75, 7-11.
[27] Zheng, H., Zhang, C., Yang, W., Wang, Y., Lin, Y., Yang, P., Yu, Q., Fan, J. and Liu, E. (2009) Fat and Cholesterol Diet Induced Lipid Metabolic Disorders and Insulin Resistance in Rabbit. Experimental and Clinical Endocrinology & Diabetes, 117, 400-405.
[28] Waqar, A.B., Koike, T., Yu, Y., Inoue, T., Aoki, T., Liu, E. and Fan, J. (2010) High-Fat Diet without Excess Calories Induces Metabolic Disorders and Enhances Atherosclerosis in Rabbits. Atherosclerosis, 213, 148-155.
[29] Varga, O., Harangi, M., Olsson, I.A. and Hansen, A.K. (2010) Contribution of Animal Models to the Understanding of the Metabolic Syndrome: A Systematic Overview. Obesity Reviews, 11, 792-807.
[30] Morelli, A., Comeglio, P., Filippi, S., Sarchielli, E., Cellai, I., Vignozzi, L., Yehiely-Cohen, R., Maneschi, E., Gacci, M., Carini, M., Adorini, L., Vannelli, G.B. and Maggi, M. (2012) Testosterone and Farnesoid X Receptor Agonist INT-747 Counteract High Fat Diet-Induced Bladder Alterations in a Rabbit Model of Metabolic Syndrome. The Journal of Steroid Biochemistry and Molecular Biology, 132, 80-92.
[31] Maneschi, E., Morelli, A., Filippi, S., Cellai, I., Comeglio, P., Mazzanti, B., Mello, T., Calcagno, A., Sarchielli, E., Vignozzi, L., Saad, F., Vettor, R., Vannelli, G.B. and Maggi, M. (2012) Testosterone Treatment Improves Metabolic Syndrome-Induced Adipose Tissue Derangements. Journal of Endocrinology, 215, 347-362.
[32] Vignozzi, L., Morelli, A., Sarchielli, E., Comeglio, P., Filippi, S., Cellai, I., Maneschi, E., Serni, S., Gacci, M., Carini, M., Piccinni, M.P., Saad, F., Adorina, L., Vannelli, G.B. and Maggi, M. (2012) Testosterone Protects from Metabolic Syndrome-Associated Prostate Inflammation: An Experimental Study in Rabbit. Journal of Endocrinology, 212, 71-84.
[33] Wang, J., Wan, R., Mo, Y., Zhang, Q., Sherwood, L.C. and Chien, S. (2010) Creating a Long-Term Diabetic Rabbit Model. Experimental Diabetes Research, 2010, Article ID: 289614.
[34] Hirabara, S.M., Gorjão, R., Vinolo, M.A., Rodrigues, A.C., Nachbar, R.T. and Curi, R. (2012) Molecular Targets Related to Inflammation and Insulin Resistance and Potential Interventions. Journal of Biomedicine and Biotechnology, 2012, Article ID: 379024.
[35] Lear, S.A., Sarna, L.K., Siow, T.J., Mancini, G.B., Siow, Y.L. and O, K. (2012) Oxidative Stress Is Associated with Visceral Adipose Tissue and Subclinical Atherosclerosis in a Healthy Multi-Ethnic Population. Applied Physiology, Nutrition, and Metabolism, 37, 1164-1170.
[36] Levenets, V.M., Lopushan, V.M., Terzov, A.I., Kharytonov, O.D. and Khindi, M. (1997) Systemic Enzyme Therapy in Orthopedics and Traumatology. Klinichna Khirurhiia, No. 9-10, 50-51.
[37] Siniachenko, O.V., Kovalenko, V.N., Mukhin, I.V., Ignatenko, G.A. and Terzov, A.I. (2000) Systemic Enzyme Therapy in Chronic Glomerulonephritis. Terapevticheskii Arkhiv, 72, 46-48.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.